Tricida Announces Multiple Data Presentations to Be Given at the Virtual National Kidney Foundation 2021 Spring Clinical Meet...
April 05 2021 - 8:30AM
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused
on the development and commercialization of its investigational
drug candidate, veverimer, a non-absorbed, orally-administered
polymer designed to treat metabolic acidosis in patients with
chronic kidney disease (CKD), announced today that multiple
presentations on the impact of metabolic acidosis and CKD and data
on veverimer will be given at the National Kidney Foundation 2021
Spring Clinical Meetings taking place from April 6 to 10, 2021.
Data from Tricida-sponsored studies on the impact of
metabolic acidosis and CKD will include the
following:
Title: |
Low Serum Bicarbonate is Associated with Excess Mortality in Kidney
Transplant Recipients |
Author: |
V. Mathur et al. |
Link: |
View poster here |
Poster #: |
275 |
|
|
Title: |
Low Serum Bicarbonate is
Associated with Graft Failure and Major Cardiovascular Outcomes in
Kidney Transplant Recipients |
Author: |
V. Mathur et al. |
Link: |
View poster here |
Poster #: |
276 |
|
|
Title: |
Increasing Serum Bicarbonate Is
Associated with Reduced Risk of Adverse Kidney Outcomes in Patients
with CKD and Metabolic Acidosis |
Author: |
N. Tangri et al. |
Link: |
View poster here |
Poster #: |
279 |
|
|
|
|
Tricida will
also present data on veverimer: |
|
Title: |
Evaluation of Potential
Physicochemical Interactions of Orally
Administered, Non-absorbed Ion-exchange Resins with
Veverimer |
Author: |
S. Tabakman et al. |
Link: |
View poster here |
Poster #: |
278 |
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the
development and commercialization of its investigational drug
candidate, veverimer, a non-absorbed, orally-administered polymer
designed to treat metabolic acidosis in patients with CKD. Tricida
is currently conducting a renal outcomes clinical trial, VALOR-CKD,
to determine if veverimer slows progression of CKD in patients with
metabolic acidosis and CKD. There are no FDA-approved treatments
for chronic metabolic acidosis, a condition commonly caused by CKD
that is believed to accelerate the progression of kidney
deterioration. It is estimated to pose a health risk to
approximately three million patients with CKD in the United
States.
For more information about Tricida, please
visit www.Tricida.com.
Contact:Jackie Cossmon, IRCTricida, Inc.Senior
Vice President of Investor Relations and
CommunicationsIR@Tricida.com
Source: Tricida, Inc.
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Apr 2023 to Apr 2024